Randomized, double-blind, phase two study of ruxolitinib plus regorafenib in patients with relapsed/refractory metastatic colorectal cancer Article (Web of Science)

Open Access Industry Collaboration International Collaboration

cited authors

  • Fogelman, David; Cubillo, Antonio; Garcia-Alfonso, Pilar; Limon Miron, Maria Luisa; Nemunaitis, John; Flora, Daniel; Borg, Christophe; Mineur, Laurent; Vieitez, Jose M.; Cohn, Allen; Saylors, Gene; Assad, Albert; Switzky, Julie; Zhou, Li; Bendell, Johanna

publication date

  • November 1, 2018

webpage

published in

author keyword

  • JAK1 protein tyrosine kinase
  • JAK2 protein tyrosine kinase
  • clinical trial
  • colorectal cancer
  • inflammation
  • ruxolitinib

category

start page

  • 5382

end page

  • 5393

volume

  • 7

issue

  • 11